Sun Pharma has signed a definitive agreement to acquire Pola Pharma for $1m.
The acquisition is part of Sun Pharma’s strategy to bolster its presence in the global dermatology market. It will add local manufacturing capabilities to the company and enable it to launch its dermatology products in Japan.
The transaction is expected to be completed by the end of January 2019.
Based in India, Sun Pharma produces generic pharmaceuticals, while Pola Pharma is a Japan-based pharmaceutical company that develops, produces and distributes dermatology products.
Genentech has entered a definitive agreement to acquire Jecure Therapeutics.
The acquisition will add Jecure’s complete portfolio of NLRP3 inhibitors. It will enable the company to combine Jecure’s research and development capabilities with its expertise in NLRP3 biology to develop therapeutics for inflammatory diseases.
Roche Group subsidiary Genentech is a biotechnology and pharmaceutical company, while Jecure Therapeutics is a biotechnology company engaged in the discovery of novel therapeutics for the treatment of non-alcoholic fatty liver disease and liver fibrosis. Both companies are based in the US.
CVS Health has completed the acquisition of Aetna for $78bn.
The company exchanged each outstanding share of Aetna common stock for $145 in cash and 0.8378 shares of CVS Health common stock.
The transaction was funded by existing cash on hand and debt financing. It is expected to generate synergies worth $750m by 2020 and support CVS Health’s growth plans.
The acquisition will create a combined company, which will deliver an innovative healthcare model to patients. Aetna will operate as a standalone company operating under CVS Health.
CVS Health is a pharmacy innovation company, while Atena is engaged in health insurance plans and dental coverage. Both companies are based in the US.